# Curtis D Klaassen

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 440 papers | 26,036 citations | 91 h-index | 133 g-index |
| 445 ext. papers | 27,796 ext. citations | 4.5 avg, IF | 7.21 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 440 | . *Drug Metabolism and Disposition*, **2021**, | 4 | 5 |
| 439 | RNA-Seq unveiled section-specific host response to lack of gut microbiota in mouse intestine. *Toxicology and Applied Pharmacology*, **2021**, 433, 115775 | 4.6 | 1 |
| 438 | Expression of cytochrome P450 isozyme transcripts and activities in human livers. *Xenobiotica*, **2021**, 51, 279-286 | 2 | 8 |
| 437 | Sex-, Age-, and Race/Ethnicity-Dependent Variations in Drug-Processing and NRF2-Regulated Genes in Human Livers. *Drug Metabolism and Disposition*, **2021**, 49, 111-119 | 4 | 3 |
| 436 | Effect of Gender and Various Diets on Bile Acid Profile and Related Genes in Mice. *Drug Metabolism and Disposition*, **2021**, 49, 62-71 | 4 | 1 |
| 435 | Activation of Nrf2 decreases bile acid concentrations in livers of female mice. *Xenobiotica*, **2021**, 51, 605-615 | 2 | 2 |
| 434 | Elucidation of OATP1B1 and 1B3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms. *Toxicology and Applied Pharmacology*, **2020**, 399, 115039 | 4.6 | 6 |
| 433 | Transplacental arsenic exposure produced 5-methylcytosine methylation changes and aberrant microRNA expressions in livers of male fetal mice. *Toxicology*, **2020**, 435, 152409 | 4.4 | 6 |
| 432 | The biotransformation of by human gut microbiota. *Xenobiotica*, **2020**, 50, 1011-1022 | 2 | 3 |
| 431 | Effects of patent ductus venosus on bile acid homeostasis in aryl hydrocarbon receptor (AhR)-null mice. *Toxicology and Applied Pharmacology*, **2020**, 403, 115136 | 4.6 | 0 |
| 430 | Effects of ablation and activation of Nrf2 on bile acid homeostasis in male mice. *Toxicology and Applied Pharmacology*, **2020**, 403, 115170 | 4.6 | 6 |
| 429 | Tissue distribution, hormonal regulation, ontogeny, diurnal expression, and induction of mouse cystine transporters Slc3a1 and Slc7a9. *Free Radical Research*, **2020**, 54, 525-534 | 4 | 2 |
| 428 | Glucocorticoids Increase Renal Excretion of Urate in Mice by Downregulating Urate Transporter 1. *Drug Metabolism and Disposition*, **2019**, 47, 1343-1351 | 4 | 6 |
| 427 | Identification and Characterization of Efflux Transporters That Modulate the Subtoxic Disposition of Diclofenac and Its Metabolites. *Drug Metabolism and Disposition*, **2019**, 47, 1080-1092 | 4 | 9 |
| 426 | The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria. *Science Advances*, **2019**, 5, eaaw6127 | 14.3 | 14 |
| 425 | Hepatic carboxylesterases are differentially regulated in PPARα-null mice treated with perfluorooctanoic acid. *Toxicology*, **2019**, 416, 15-22 | 4.4 | 9 |
| 424 | RNA-Seq provides new insights on the relative mRNA abundance of antioxidant components during mouse liver development. *Free Radical Biology and Medicine*, **2019**, 134, 335-342 | 7.8 | 6 |

| | | | |
|---|---|---|---|
| 423 | Oleanolic acid reprograms the liver to protect against hepatotoxicants, but is hepatotoxic at high doses. *Liver International*, **2019**, 39, 427-439 | 7.9 | 25 |
| 422 | Effects of Absence of Constitutive Androstane Receptor (CAR) on Bile Acid Homeostasis in Male and Female Mice. *Toxicological Sciences*, **2019**, | 4.4 | 3 |
| 421 | Aryl hydrocarbon receptor (AhR) mediated short-term effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on bile acid homeostasis in mice. *Toxicology and Applied Pharmacology*, **2018**, 343, 48-61 | 4.6 | 10 |
| 420 | The Life and Times of John Doull, PhD, MD (1922-2017). *Toxicological Sciences*, **2018**, 162, 5-11 | 4.4 | 0 |
| 419 | Alteration of Bile Acid and Cholesterol Biosynthesis and Transport by Perfluorononanoic Acid (PFNA) in Mice. *Toxicological Sciences*, **2018**, 162, 225-233 | 4.4 | 15 |
| 418 | From Classical Toxicology to Tox21: Some Critical Conceptual and Technological Advances in the Molecular Understanding of the Toxic Response Beginning From the Last Quarter of the 20th Century. *Toxicological Sciences*, **2018**, 161, 5-22 | 4.4 | 21 |
| 417 | From the Cover: Identification of Natural Products as Inhibitors of Human Organic Anion Transporters (OAT1 and OAT3) and Their Protective Effect on Mercury-Induced Toxicity. *Toxicological Sciences*, **2018**, 161, 321-334 | 4.4 | 14 |
| 416 | Activation of Nrf2 in the liver is associated with stress resistance mediated by suppression of the growth hormone-regulated STAT5b transcription factor. *PLoS ONE*, **2018**, 13, e0200004 | 3.7 | 26 |
| 415 | Activation of PPARα decreases bile acids in livers of female mice while maintaining bile flow and biliary bile acid excretion. *Toxicology and Applied Pharmacology*, **2018**, 338, 112-123 | 4.6 | 7 |
| 414 | Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21 International Symposium on Microsomes and Drug Oxidations (MDO). *Acta Pharmaceutica Sinica B*, **2017**, 7, 241-248 | 15.5 | 17 |
| 413 | Persistent alterations in immune cell populations and function from a single dose of perfluorononanoic acid (PFNA) in C57Bl/6 mice. *Food and Chemical Toxicology*, **2017**, 100, 24-33 | 4.7 | 11 |
| 412 | RNA-Seq Profiling of Intestinal Expression of Xenobiotic Processing Genes in Germ-Free Mice. *Drug Metabolism and Disposition*, **2017**, 45, 1225-1238 | 4 | 25 |
| 411 | Effect of nine diets on mRNAs of phase-II conjugation enzymes in livers of mice. *Xenobiotica*, **2017**, 47, 645-654 | 2 | 2 |
| 410 | Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner. *Toxicological Sciences*, **2017**, 160, 351-360 | 4.4 | 13 |
| 409 | RNA Sequencing Quantification of Xenobiotic-Processing Genes in Various Sections of the Intestine in Comparison to the Liver of Male Mice. *Drug Metabolism and Disposition*, **2016**, 44, 842-56 | 4 | 29 |
| 408 | Upholding science in health, safety and environmental risk assessments and regulations. *Toxicology* , **2016**, 371, 12-16 | 4.4 | 5 |
| 407 | Dose-response effect of berberine on bile acid profile and gut microbiota in mice. *BMC Complementary and Alternative Medicine*, **2016**, 16, 394 | 4.7 | 38 |
| 406 | Activation of Constitutive Androstane Receptor (CAR) in Mice Results in Maintained Biliary Excretion of Bile Acids Despite a Marked Decrease of Bile Acids in Liver. *Toxicological Sciences*, **2016** , 151, 403-18 | 4.4 | 16 |

| | | | |
|---|---|---|---|
| 405 | Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics. *Drug Metabolism and Disposition*, **2016**, 44, 262-74 | 4 | 79 |
| 404 | Age-Specific Regulation of Drug-Processing Genes in Mouse Liver by Ligands of Xenobiotic-Sensing Transcription Factors. *Drug Metabolism and Disposition*, **2016**, 44, 1038-49 | 4 | 22 |
| 403 | RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2016**, 1859, 1198-1217 | 6 | 46 |
| 402 | Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in Mice. *Drug Metabolism and Disposition*, **2016**, 44, 366-9 | 4 | 6 |
| 401 | Effect of various diets on the expression of phase-I drug-metabolizing enzymes in livers of mice. *Xenobiotica*, **2015**, 45, 586-97 | 2 | 10 |
| 400 | Effect of nine diets on xenobiotic transporters in livers of mice. *Xenobiotica*, **2015**, 45, 634-41 | 2 | 3 |
| 399 | Importance of Large Intestine in Regulating Bile Acids and Glucagon-Like Peptide-1 in Germ-Free Mice. *Drug Metabolism and Disposition*, **2015**, 43, 1544-56 | 4 | 58 |
| 398 | Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids. *Drug Metabolism and Disposition*, **2015**, 43, 1505-21 | 4 | 129 |
| 397 | Screening a mouse liver gene expression compendium identifies modulators of the aryl hydrocarbon receptor (AhR). *Toxicology*, **2015**, 336, 99-112 | 4.4 | 39 |
| 396 | Protection against phalloidin-induced liver injury by oleanolic acid involves Nrf2 activation and suppression of Oatp1b2. *Toxicology Letters*, **2015**, 232, 326-32 | 4.4 | 29 |
| 395 | The Role of Sirt1 in Bile Acid Regulation during Calorie Restriction in Mice. *PLoS ONE*, **2015**, 10, e0138307 | 3.7 | 8 |
| 394 | Deciphering the Developmental Dynamics of the Mouse Liver Transcriptome. *PLoS ONE*, **2015**, 10, e0141220 | 3.7 | 24 |
| 393 | Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendium. *Nuclear Receptor Signaling*, **2015**, 13, e002 | 1 | 61 |
| 392 | RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice. *Drug Metabolism and Disposition*, **2015**, 43, 1572-80 | 4 | 77 |
| 391 | Individual bile acids have differential effects on bile acid signaling in mice. *Toxicology and Applied Pharmacology*, **2015**, 283, 57-64 | 4.6 | 54 |
| 390 | Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR). *Toxicology and Applied Pharmacology*, **2014**, 278, 65-71 | 4.6 | 29 |
| 389 | Learning to program the liver. *Annual Review of Pharmacology and Toxicology*, **2014**, 54, 1-8 | 17.9 | 9 |
| 388 | Short-term calorie restriction feminizes the mRNA profiles of drug metabolizing enzymes and transporters in livers of mice. *Toxicology and Applied Pharmacology*, **2014**, 274, 137-46 | 4.6 | 25 |

| | | | |
|---|---|---|---|
| 387 | H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G219-28 | 5.1 | 13 |
| 386 | Decreased bile-acid synthesis in livers of hepatocyte-conditional NADPH-cytochrome P450 reductase-null mice results in increased bile acids in serum. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 351, 105-13 | 4.7 | 6 |
| 385 | Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. *Toxicological Sciences*, **2014**, 141, 538-46 | 4.4 | 56 |
| 384 | Synergistic interaction between genetics and disease on pravastatin disposition. *Journal of Hepatology*, **2014**, 61, 139-47 | 13.4 | 38 |
| 383 | Overexpression of Nrf2 protects against microcystin-induced hepatotoxicity in mice. *PLoS ONE*, **2014**, 9, e93013 | 3.7 | 20 |
| 382 | Ontogeny of hepatic energy metabolism genes in mice as revealed by RNA-sequencing. *PLoS ONE*, **2014**, 9, e104560 | 3.7 | 12 |
| 381 | Screening of natural compounds as activators of the keap1-nrf2 pathway. *Planta Medica*, **2014**, 80, 97-104 | 3.1 | 64 |
| 380 | Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. *Journal of Lipid Research*, **2014**, 55, 2576-86 | 6.3 | 34 |
| 379 | Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes. *Drug Metabolism and Disposition*, **2014**, 42, 1826-33 | 4 | 5 |
| 378 | Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. *Toxicology and Applied Pharmacology*, **2014**, 277, 138-45 | 4.6 | 76 |
| 377 | Nrf2 protects against furosemide-induced hepatotoxicity. *Toxicology*, **2014**, 324, 35-42 | 4.4 | 18 |
| 376 | Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis. *PLoS ONE*, **2014**, 9, e88584 | 3.7 | 63 |
| 375 | Organic anion-transporting polypeptide 1a4 (Oatp1a4) is important for secondary bile acid metabolism. *Biochemical Pharmacology*, **2013**, 86, 437-45 | 6 | 17 |
| 374 | Increased bile acids in enterohepatic circulation by short-term calorie restriction in male mice. *Toxicology and Applied Pharmacology*, **2013**, 273, 680-90 | 4.6 | 36 |
| 373 | Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice. *Toxicology and Applied Pharmacology*, **2013**, 272, 816-24 | 4.6 | 32 |
| 372 | RNA-sequencing quantification of hepatic ontogeny of phase-I enzymes in mice. *Drug Metabolism and Disposition*, **2013**, 41, 2175-86 | 4 | 25 |
| 371 | Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. *Nature Medicine*, **2013**, 19, 418-20 | 50.5 | 107 |
| 370 | Expression of human CAR splicing variants in BAC-transgenic mice. *Toxicological Sciences*, **2013**, 132, 142-50 | 4.4 | 6 |

| | | | |
|---|---|---|---|
| 369 | Tissue distribution, ontogeny, and chemical induction of aldo-keto reductases in mice. *Drug Metabolism and Disposition*, **2013**, 41, 1480-7 | 4 | 23 |
| 368 | RNA-sequencing quantification of hepatic ontogeny and tissue distribution of mRNAs of phase II enzymes in mice. *Drug Metabolism and Disposition*, **2013**, 41, 844-57 | 4 | 33 |
| 367 | Hormonal regulation of Cyp4a isoforms in mouse liver and kidney. *Xenobiotica*, **2013**, 43, 1055-63 | 2 | 28 |
| 366 | CDDO-9,11-dihydro-trifluoroethyl amide (CDDO-dhTFEA) induces hepatic cytoprotective genes and increases bile flow in rats. *Xenobiotica*, **2013**, 43, 571-8 | 2 | 11 |
| 365 | Genetic activation of Nrf2 protects against fasting-induced oxidative stress in livers of mice. *PLoS ONE*, **2013**, 8, e59122 | 3.7 | 56 |
| 364 | Nrf2 protection against liver injury produced by various hepatotoxicants. *Oxidative Medicine and Cellular Longevity*, **2013**, 2013, 305861 | 6.7 | 108 |
| 363 | Acute Immunotoxic Effects of Perfluorononanoic Acid (PFNA) in C57BL/6 Mice. *Clinical & Experimental Pharmacology*, **2013**, Suppl 4, | 1 | 5 |
| 362 | Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity. *Toxicology and Applied Pharmacology*, **2012**, 261, 189-95 | 4.6 | 12 |
| 361 | Repeated administration of berberine inhibits cytochromes P450 in humans. *European Journal of Clinical Pharmacology*, **2012**, 68, 213-7 | 2.8 | 68 |
| 360 | RNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development. *Drug Metabolism and Disposition*, **2012**, 40, 1198-209 | 4 | 46 |
| 359 | RNA-Seq reveals different mRNA abundance of transporters and their alternative transcript isoforms during liver development. *Toxicological Sciences*, **2012**, 127, 592-608 | 4.4 | 37 |
| 358 | Role of Nrf2 in preventing ethanol-induced oxidative stress and lipid accumulation. *Toxicology and Applied Pharmacology*, **2012**, 262, 321-9 | 4.6 | 105 |
| 357 | Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPAR□ and Nrf2-null mice. *Drug Metabolism and Disposition*, **2012**, 40, 1366-79 | 4 | 185 |
| 356 | Th2 skewing by activation of Nrf2 in CD4(+) T cells. *Journal of Immunology*, **2012**, 188, 1630-7 | 5.3 | 80 |
| 355 | Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. *Cell Metabolism*, **2012**, 15, 65-74 | 24.6 | 84 |
| 354 | Nrf2 activation prevents cadmium-induced acute liver injury. *Toxicology and Applied Pharmacology*, **2012**, 263, 14-20 | 4.6 | 106 |
| 353 | Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet. *Toxicology and Applied Pharmacology*, **2012**, 264, 305-14 | 4.6 | 58 |
| 352 | Gender-divergent profile of bile acid homeostasis during aging of mice. *PLoS ONE*, **2012**, 7, e32551 | 3.7 | 43 |

| | | | |
|---|---|---|---|
| 351 | Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice. *PLoS ONE*, **2012**, 7, e34522 | 3.7 | 30 |
| 350 | Diurnal variation of hepatic antioxidant gene expression in mice. *PLoS ONE*, **2012**, 7, e44237 | 3.7 | 99 |
| 349 | Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway. *PLoS ONE*, **2012**, 7, e44686 | 3.7 | 25 |
| 348 | Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. *Hepatology*, **2012**, 56, 1034-43 | 11.2 | 259 |
| 347 | Effect of bile duct ligation on bile acid composition in mouse serum and liver. *Liver International*, **2012**, 32, 58-69 | 7.9 | 119 |
| 346 | Repression of hepatobiliary transporters and differential regulation of classic and alternative bile acid pathways in mice during pregnancy. *Toxicological Sciences*, **2012**, 130, 257-68 | 4.4 | 24 |
| 345 | Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice. *American Journal of Physiology - Renal Physiology*, **2012**, 302, G979-96 | 5.1 | 34 |
| 344 | Hepatic ontogeny and tissue distribution of mRNAs of epigenetic modifiers in mice using RNA-sequencing. *Epigenetics*, **2012**, 7, 914-29 | 5.7 | 27 |
| 343 | Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury. *Toxicological Sciences*, **2012**, 127, 451-62 | 4.4 | 16 |
| 342 | Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice. *Drug Metabolism and Disposition*, **2012**, 40, 1216-25 | 4 | 46 |
| 341 | Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. *Journal of Biological Chemistry*, **2012**, 287, 1861-73 | 5.4 | 141 |
| 340 | Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice. *Drug Metabolism and Disposition*, **2012**, 40, 1191-7 | 4 | 40 |
| 339 | Hormonal and chemical regulation of paraoxonases in mice. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 342, 688-95 | 4.7 | 18 |
| 338 | Nrf2 protects against diquat-induced liver and lung injury. *Free Radical Research*, **2012**, 46, 1220-9 | 4 | 32 |
| 337 | Ontogeny of novel cytochrome P450 gene isoforms during postnatal liver maturation in mice. *Drug Metabolism and Disposition*, **2012**, 40, 1226-37 | 4 | 42 |
| 336 | Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver. *PLoS ONE*, **2012**, 7, e39006 | 3.7 | 103 |
| 335 | The Nrf2 activator, tBHQ, inhibits the early production of IL-2, but not CD69 induction, in primary murine splenocytes and human Jurkat T cells. *FASEB Journal*, **2012**, 26, lb598 | 0.9 | |
| 334 | Epigenetic regulation of drug processing genes. *Toxicology Mechanisms and Methods*, **2011**, 21, 312-24 | 3.6 | 25 |

| | | | |
|---|---|---|---|
| 333 | Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. *Toxicological Sciences*, **2011**, 124, 261-77 | 4.4 | 124 |
| 332 | Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. *Journal of Ethnopharmacology*, **2011**, 138, 111-8 | 5 | 38 |
| 331 | Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters. *PLoS ONE*, **2011**, 6, e16683 | 3.7 | 79 |
| 330 | Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. *Toxicology and Applied Pharmacology*, **2011**, 256, 122-35 | 4.6 | 57 |
| 329 | Organic anion transporting polypeptides in the hepatic uptake of PBDE congeners in mice. *Toxicology and Applied Pharmacology*, **2011**, 257, 23-31 | 4.6 | 9 |
| 328 | Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice. *Hepatology*, **2011**, 53, 272-81 | 11.2 | 84 |
| 327 | Final report of the safety assessment of cosmetic ingredients derived from Zea mays (corn). *International Journal of Toxicology*, **2011**, 30, 17S-39S | 2.4 | 7 |
| 326 | CYP2D plays a major role in berberine metabolism in liver of mice and humans. *Xenobiotica*, **2011**, 41, 996-1005 | 2 | 50 |
| 325 | Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles. *Toxicological Sciences*, **2011**, 122, 587-97 | 4.4 | 34 |
| 324 | Beneficial role of Nrf2 in regulating NADPH generation and consumption. *Toxicological Sciences*, **2011**, 123, 590-600 | 4.4 | 220 |
| 323 | Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. *Toxicological Sciences*, **2011**, 123, 359-67 | 4.4 | 97 |
| 322 | Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults). *Xenobiotica*, **2011**, 41, 187-97 | 2 | 43 |
| 321 | Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability. *Toxicological Sciences*, **2011**, 124, 251-60 | 4.4 | 19 |
| 320 | Energy restriction does not compensate for the reduced expression of hepatic drug-processing genes in mice with aging. *Drug Metabolism and Disposition*, **2010**, 38, 1122-31 | 4 | 14 |
| 319 | Characterization of peroxisome proliferator-activated receptor alpha--independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. *Toxicological Sciences*, **2010**, 113, 45-59 | 4.4 | 56 |
| 318 | ChIPing the cistrome of PXR in mouse liver. *Nucleic Acids Research*, **2010**, 38, 7943-63 | 20.1 | 54 |
| 317 | Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. *Journal of Lipid Research*, **2010**, 51, 3230-42 | 6.3 | 107 |
| 316 | Genetic and epigenetic regulation and expression signatures of glutathione S-transferases in developing mouse liver. *Toxicological Sciences*, **2010**, 116, 32-43 | 4.4 | 31 |

| | | | |
|---|---|---|---|
| 315 | Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 333, 140-51 | 4.7 | 79 |
| 314 | Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 335, 2-12 | 4.7 | 138 |
| 313 | Nuclear receptor-mediated regulation of carboxylesterase expression and activity. *Expert Opinion on Drug Metabolism and Toxicology*, **2010**, 6, 261-71 | 5.5 | 44 |
| 312 | Xenobiotic, bile acid, and cholesterol transporters: function and regulation. *Pharmacological Reviews*, **2010**, 62, 1-96 | 22.5 | 595 |
| 311 | Differential effects of polychlorinated biphenyl congeners on serum thyroid hormone levels in rats. *Toxicological Sciences*, **2010**, 117, 36-44 | 4.4 | 49 |
| 310 | Role of UDP-glucuronosyltransferase (UGT) 2B2 in metabolism of triiodothyronine: effect of microsomal enzyme inducers in Sprague Dawley and UGT2B2-deficient Fischer 344 rats. *Toxicological Sciences*, **2010**, 116, 413-21 | 4.4 | 16 |
| 309 | Oxidative stress and the pathogenesis of cholestasis. *Seminars in Liver Disease*, **2010**, 30, 195-204 | 7.3 | 137 |
| 308 | Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. *Toxicology and Applied Pharmacology*, **2010**, 244, 57-65 | 4.6 | 282 |
| 307 | Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. *Toxicology and Applied Pharmacology*, **2010**, 245, 326-34 | 4.6 | 136 |
| 306 | Molecular targets of epigenetic regulation and effectors of environmental influences. *Toxicology and Applied Pharmacology*, **2010**, 245, 378-93 | 4.6 | 94 |
| 305 | Disruption of thyroid hormone homeostasis in Ugt1a-deficient Gunn rats by microsomal enzyme inducers is not due to enhanced thyroxine glucuronidation. *Toxicology and Applied Pharmacology*, **2010**, 248, 38-44 | 4.6 | 13 |
| 304 | Nrf2 activation enhances biliary excretion of sulfobromophthalein by inducing glutathione-S-transferase activity. *Toxicological Sciences*, **2009**, 109, 24-30 | 4.4 | 17 |
| 303 | Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. *Drug Metabolism and Disposition*, **2009**, 37, 847-56 | 4 | 121 |
| 302 | Genetic polymorphisms in the TATA box and upstream phenobarbital-responsive enhancer module of the UGT1A1 promoter have combined effects on UDP-glucuronosyltransferase 1A1 transcription mediated by constitutive androstane receptor, pregnane X receptor, or glucocorticoid receptor in human liver. *Drug Metabolism and Disposition*, **2009**, 37, 1870-81 | 4 | 18 |
| 301 | Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. *Toxicological Sciences*, **2009**, 108, 35-47 | 4.4 | 124 |
| 300 | Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. *Drug Metabolism and Disposition*, **2009**, 37, 834-40 | 4 | 50 |
| 299 | Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. *Drug Metabolism and Disposition*, **2009**, 37, 203-10 | 4 | 94 |
| 298 | Introducing the "TCDD-inducible AhR-Nrf2 gene battery". *Toxicological Sciences*, **2009**, 111, 238-46 | 4.4 | 205 |

| | | | |
|---|---|---|---|
| 297 | Role of hepatic transporters in prevention of bile acid toxicity after partial hepatectomy in mice. *American Journal of Physiology - Renal Physiology*, **2009**, 297, G419-33 | 5.1 | 46 |
| 296 | Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. *Toxicological Sciences*, **2009**, 110, 47-60 | 4.4 | 90 |
| 295 | Hepatobiliary disposition of thyroid hormone in Mrp2-deficient TR- rats: reduced biliary excretion of thyroxine glucuronide does not prevent xenobiotic-induced hypothyroidism. *Toxicological Sciences*, **2009**, 108, 482-91 | 4.4 | 21 |
| 294 | Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. *Drug Metabolism and Disposition* , **2009**, 37, 1035-45 | 4 | 55 |
| 293 | Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. *Toxicological Sciences*, **2009**, 109, 31-40 | 4.4 | 69 |
| 292 | Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. *Drug Metabolism and Disposition*, **2009**, 37, 2178-85 | 4 | 57 |
| 291 | Three patterns of cytochrome P450 gene expression during liver maturation in mice. *Drug Metabolism and Disposition*, **2009**, 37, 116-21 | 4 | 78 |
| 290 | ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. *Toxicological Sciences*, **2009**, 108, 247-57 | 4.4 | 85 |
| 289 | Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. *Molecular Pharmacology*, **2009**, 75, 1171-9 | 4.3 | 60 |
| 288 | Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice. *Toxicology and Applied Pharmacology*, **2009**, 234, 166-78 | 4.6 | 18 |
| 287 | CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. *Toxicology and Applied Pharmacology*, **2009**, 236, 109-14 | 4.6 | 87 |
| 286 | Metallothionein protection of cadmium toxicity. *Toxicology and Applied Pharmacology*, **2009**, 238, 215-20 | 4.6 | 467 |
| 285 | Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. *Biochemical Pharmacology*, **2009**, 77, 1273-82 | 6 | 137 |
| 284 | Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. *Drug Metabolism and Disposition*, **2009**, 37, 106-15 | 4 | 130 |
| 283 | Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice. *Toxicology Letters*, **2009**, 188, 38-44 | 4.4 | 13 |
| 282 | Ontogenic expression of hepatic Ahr mRNA is associated with histone H3K4 di-methylation during mouse liver development. *Toxicology Letters*, **2009**, 189, 184-90 | 4.4 | 12 |
| 281 | Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. *Toxicology and Applied Pharmacology*, **2008**, 226, 74-83 | 4.6 | 122 |
| 280 | Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. *Toxicology and Applied Pharmacology*, **2008**, 231, 364-73 | 4.6 | 53 |

| | | | |
|---|---|---|---|
| 279 | Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. *Life Sciences*, **2008**, 83, 59-64 | 6.8 | 55 |
| 278 | Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. *Drug Metabolism and Disposition*, **2008**, 36, 1960-70 | 4 | 42 |
| 277 | Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. *Toxicological Sciences*, **2008**, 106, 329-38 | 4.4 | 61 |
| 276 | Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. *Toxicological Sciences*, **2008**, 106, 37-45 | 4.4 | 42 |
| 275 | Ischemia-reperfusion of rat livers decreases liver and increases kidney multidrug resistance associated protein 2 (Mrp2). *Toxicological Sciences*, **2008**, 101, 171-8 | 4.4 | 34 |
| 274 | Xenobiotic transporters: ascribing function from gene knockout and mutation studies. *Toxicological Sciences*, **2008**, 101, 186-96 | 4.4 | 100 |
| 273 | Perfluorocarboxylic acids induce cytochrome P450 enzymes in mouse liver through activation of PPAR-alpha and CAR transcription factors. *Toxicological Sciences*, **2008**, 106, 29-36 | 4.4 | 68 |
| 272 | Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. *Toxicological Sciences*, **2008**, 103, 35-45 | 4.4 | 129 |
| 271 | Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. *Toxicological Sciences*, **2008**, 106, 319-28 | 4.4 | 86 |
| 270 | NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325, 655-64 | 4.7 | 190 |
| 269 | Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. *Toxicological Sciences*, **2008**, 101, 51-64 | 4.4 | 106 |
| 268 | Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 612-21 | 4.7 | 75 |
| 267 | The Nrf2 activator oltipraz also activates the constitutive androstane receptor. *Drug Metabolism and Disposition*, **2008**, 36, 1716-21 | 4 | 40 |
| 266 | Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2008**, 873, 209-17 | 3.2 | 192 |
| 265 | Inhibition of IFN production by the nrf2 activators, tBHQ and BHA, in activated murine T cells. *FASEB Journal*, **2008**, 22, 1139.4 | 0.9 | 1 |
| 264 | Genetic polymorphisms in the RNA polymerase II core promoter and enhancer elements of the UGT1A1 promoter influence activation of its gene transcription. *FASEB Journal*, **2008**, 22, 921.16 | 0.9 | |
| 263 | Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. *Hepatology*, **2007**, 46, 1597-610 | 11.2 | 255 |
| 262 | Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen. *Toxicology*, **2007**, 230, 197-206 | 4.4 | 45 |

| | | | |
|---|---|---|---|
| 261 | Regulation of hepatic bile acid transporters Ntcp and Bsep expression. *Biochemical Pharmacology*, **2007**, 74, 1665-76 | 6 | 65 |
| 260 | Regulation of metal transporters by dietary iron, and the relationship between body iron levels and cadmium uptake. *Archives of Toxicology*, **2007**, 81, 327-34 | 5.8 | 72 |
| 259 | Hepatic ischemia-reperfusion induces renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice. *Molecular Pharmacology*, **2007**, 71, 817-25 | 4.3 | 58 |
| 258 | Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. *Drug Metabolism and Disposition*, **2007**, 35, 995-1000 | 4 | 102 |
| 257 | Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. *Drug Metabolism and Disposition*, **2007**, 35, 121-7 | 4 | 141 |
| 256 | Influence of phenobarbital on morphine metabolism and disposition: LC-MS/MS determination of morphine (M) and morphine-3-glucuronide (M3G) in Wistar-Kyoto rat serum, bile, and urine. *Current Drug Metabolism*, **2007**, 8, 79-89 | 3.5 | 7 |
| 255 | Constitutive mRNA expression of various glutathione S-transferase isoforms in different tissues of mice. *Toxicological Sciences*, **2007**, 100, 513-24 | 4.4 | 74 |
| 254 | The flame retardants, polybrominated diphenyl ethers, are pregnane X receptor activators. *Toxicological Sciences*, **2007**, 97, 94-102 | 4.4 | 118 |
| 253 | Activation of cAMP-dependent signaling pathway induces mouse organic anion transporting polypeptide 2 expression. *Molecular Pharmacology*, **2007**, 71, 1159-64 | 4.3 | 5 |
| 252 | Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport. *Drug Metabolism and Disposition*, **2007**, 35, 1806-15 | 4 | 65 |
| 251 | Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. *Pharmacogenetics and Genomics*, **2007**, 17, 103-14 | 1.9 | 15 |
| 250 | Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. *Biochimica Et Biophysica Acta - Biomembranes*, **2007**, 1768, 637-47 | 3.8 | 58 |
| 249 | Tissue distribution and ontogeny of sulfotransferase enzymes in mice. *Toxicological Sciences*, **2006**, 93, 242-55 | 4.4 | 161 |
| 248 | Endocrine regulation of gender-divergent mouse organic anion-transporting polypeptide (Oatp) expression. *Molecular Pharmacology*, **2006**, 70, 1291-7 | 4.3 | 41 |
| 247 | Acquired cadmium resistance in metallothionein-I/II(-/-) knockout cells: role of the T-type calcium channel Cacnalpha1G in cadmium uptake. *Molecular Pharmacology*, **2006**, 69, 629-39 | 4.3 | 44 |
| 246 | Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 317, 537-45 | 4.7 | 64 |
| 245 | Regulation of mRNA expression of xenobiotic transporters by the pregnane x receptor in mouse liver, kidney, and intestine. *Drug Metabolism and Disposition*, **2006**, 34, 1863-7 | 4 | 64 |
| 244 | Tissue distribution and ontogeny of organic cation transporters in mice. *Drug Metabolism and Disposition*, **2006**, 34, 477-82 | 4 | 115 |

| | | | |
|---|---|---|---|
| 243 | Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. *International Journal of Toxicology*, **2006**, 25, 231-59 | 2.4 | 305 |
| 242 | Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. *Transplantation*, **2006**, 82, 258-66 | 1.8 | 34 |
| 241 | Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. *Cell Stress and Chaperones*, **2006**, 11, 356-63 | 4 | 43 |
| 240 | Lipopolysaccharide-induced down-regulation of organic anion transporting polypeptide 4 (Oatp4; Slc21a10) is independent of tumor necrosis factor-alpha, Interleukin-1beta, interleukin-6, or inducible nitric oxide synthase. *Toxicological Sciences*, **2005**, 83, 197-203 | 4.4 | 9 |
| 239 | Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. *Biochemical and Biophysical Research Communications*, **2005**, 326, 181-7 | 3.4 | 160 |
| 238 | Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats. *Biochemical Pharmacology*, **2005**, 70, 1088-95 | 6 | 48 |
| 237 | Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). *Drug Metabolism and Disposition*, **2005**, 33, 1062-73 | 4 | 140 |
| 236 | Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. *Toxicological Sciences*, **2005**, 83, 44-52 | 4.4 | 105 |
| 235 | Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. *Drug Metabolism and Disposition*, **2005**, 33, 947-55 | 4 | 172 |
| 234 | Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. *Drug Metabolism and Disposition*, **2005**, 33, 956-62 | 4 | 219 |
| 233 | Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. *Drug Metabolism and Disposition*, **2005**, 33, 1276-82 | 4 | 107 |
| 232 | DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4). *Drug Metabolism and Disposition*, **2004**, 32, 1265-1271 | 4 | 19 |
| 231 | Bromobenzene-induced hepatotoxicity at the transcriptome level. *Toxicological Sciences*, **2004**, 79, 411-22 | 4.4 | 71 |
| 230 | Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. *Drug Metabolism and Disposition*, **2004**, 32, 734-41 | 4 | 126 |
| 229 | Promotion of thyroid tumors in rats by pregnenolone-16alpha-carbonitrile (PCN) and polychlorinated biphenyl (PCB). *Toxicological Sciences*, **2004**, 81, 50-9 | 4.4 | 25 |
| 228 | Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. *Drug Metabolism and Disposition*, **2004**, 32, 620-5 | 4 | 122 |
| 227 | Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice. *Molecular and Cellular Biochemistry*, **2004**, 255, 11-8 | 4.2 | 24 |
| 226 | Dietary iron regulates intestinal cadmium absorption through iron transporters in rats. *Toxicology Letters*, **2004**, 152, 19-25 | 4.4 | 114 |

| | | | |
|---|---|---|---|
| 225 | Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. *Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology*, **2004**, 139, 209-18 | 3.2 | 24 |
| 224 | Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. *Biochemical and Biophysical Research Communications*, **2004**, 317, 46-53 | 3.4 | 55 |
| 223 | The presence of xenobiotic transporters in rat placenta. *Drug Metabolism and Disposition*, **2003**, 31, 153-67 | 4 | 108 |
| 222 | Endocrine regulation of rat organic anion transporters. *Drug Metabolism and Disposition*, **2003**, 31, 559-64 | 4 | 56 |
| 221 | Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. *Drug Metabolism and Disposition*, **2003**, 31, 1337-45 | 4 | 145 |
| 220 | Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. *Drug Metabolism and Disposition*, **2003**, 31, 908-15 | 4 | 97 |
| 219 | Cadmium accumulation and detoxification by alveolar macrophages of cigarette smokers. *Chest*, **2003**, 124, 1924-8 | 5.3 | 30 |
| 218 | Induction of T(4) UDP-GT activity, serum thyroid stimulating hormone, and thyroid follicular cell proliferation in mice treated with microsomal enzyme inducers. *Toxicology and Applied Pharmacology*, **2003**, 188, 6-13 | 4.6 | 60 |
| 217 | Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. *Drug Metabolism and Disposition*, **2003**, 31, 1315-9 | 4 | 57 |
| 216 | Increase in rat liver UDP-glucuronosyltransferase mRNA by microsomal enzyme inducers that enhance thyroid hormone glucuronidation. *Drug Metabolism and Disposition*, **2002**, 30, 240-6 | 4 | 63 |
| 215 | Acute cadmium exposure induces stress-related gene expression in wild-type and metallothionein-I/II-null mice. *Free Radical Biology and Medicine*, **2002**, 32, 525-35 | 7.8 | 59 |
| 214 | Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. *Toxicology*, **2002**, 170, 55-62 | 4.4 | 67 |
| 213 | Testicular toxicity of di-(2-ethylhexyl)phthalate in young Sprague-Dawley rats. *Toxicology*, **2002**, 171, 105-15 | 4.4 | 125 |
| 212 | iNOS-null mice are not resistant to cadmium chloride-induced hepatotoxicity. *Toxicology*, **2002**, 175, 83-90 | 4.4 | 29 |
| 211 | Expression of rat Multidrug Resistance Protein 2 (Mrp2) in male and female rats during normal and pregnenolone-16alpha-carbonitrile (PCN)-induced postnatal ontogeny. *Toxicology*, **2002**, 178, 209-19 | 4.4 | 31 |
| 210 | Tumor necrosis factor-alpha-null mice are not resistant to cadmium chloride-induced hepatotoxicity. *Toxicology and Applied Pharmacology*, **2002**, 179, 155-62 | 4.6 | 32 |
| 209 | Role of rat multidrug resistance protein 2 in plasma and biliary disposition of dibromosulfophthalein after microsomal enzyme induction. *Toxicology and Applied Pharmacology*, **2002**, 180, 56-63 | 4.6 | 7 |
| 208 | Gadolinium chloride pretreatment prevents cadmium chloride-induced liver damage in both wild-type and MT-null mice. *Toxicology and Applied Pharmacology*, **2002**, 180, 178-85 | 4.6 | 44 |

| | | | |
|---|---|---|---|
| 207 | Cadmium absorption and its relationship to divalent metal transporter-1 in the pregnant rat. *Toxicology and Applied Pharmacology*, **2002**, 185, 18-24 | 4.6 | 70 |
| 206 | Xenobiotic transporters: another protective mechanism for chemicals. *International Journal of Toxicology*, **2002**, 21, 7-12 | 2.4 | 15 |
| 205 | Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. *Molecular Pharmacology*, **2002**, 61, 832-9 | 4.3 | 117 |
| 204 | Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 300, 97-104 | 4.7 | 198 |
| 203 | Gender-specific and developmental influences on the expression of rat organic anion transporters. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 301, 145-51 | 4.7 | 166 |
| 202 | Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 301, 551-60 | 4.7 | 80 |
| 201 | Tissue distribution and chemical induction of multiple drug resistance genes in rats. *Drug Metabolism and Disposition*, **2002**, 30, 838-44 | 4 | 129 |
| 200 | Analysis of strain difference in sensitivity to cadmium-induced hepatotoxicity in Fischer 344 and Sprague-Dawley rats. *Toxicological Sciences*, **2002**, 67, 329-40 | 4.4 | 16 |
| 199 | Postnatal expression and induction by pregnenolone-16alpha-carbonitrile of the organic anion-transporting polypeptide 2 in rat liver. *Drug Metabolism and Disposition*, **2002**, 30, 283-8 | 4 | 42 |
| 198 | Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. *Toxicological Sciences*, **2002**, 67, 182-9 | 4.4 | 70 |
| 197 | Intestinal absorption of cadmium is associated with divalent metal transporter 1 in rats. *Toxicological Sciences*, **2002**, 68, 288-94 | 4.4 | 136 |
| 196 | Effect of microsomal enzyme inducers on the biliary excretion of triiodothyronine (T(3)) and its metabolites. *Toxicological Sciences*, **2002**, 65, 184-91 | 4.4 | 45 |
| 195 | Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. *Toxicological Sciences*, **2002**, 66, 16-26 | 4.4 | 46 |
| 194 | Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 300, 206-12 | 4.7 | 60 |
| 193 | Determination of transcription start site and analysis of promoter sequence, splice junction sites, intron sequence and codon usage bias of rat liver-specific organic anion transporter-1 (rlst-1/Oatp-4/Slc21a10) gene. *DNA Sequence*, **2002**, 13, 103-7 | | 4 |
| 192 | Protective effect of metallothionein against the toxicity of cadmium and other metals(1). *Toxicology*, **2001**, 163, 93-100 | 4.4 | 178 |
| 191 | Cyproterone acetate induces a cellular tolerance to cadmium in rat liver epithelial cells involving reduced cadmium accumulation. *Toxicology*, **2001**, 165, 13-25 | 4.4 | 19 |
| 190 | Metallothionein-null and wild-type mice show similar cadmium absorption and tissue distribution following oral cadmium administration. *Toxicology and Applied Pharmacology*, **2001**, 175, 253-9 | 4.6 | 33 |

| | | | |
|---|---|---|---|
| 189 | Genetic background but not metallothionein phenotype dictates sensitivity to cadmium-induced testicular injury in mice. *Toxicology and Applied Pharmacology*, **2001**, 176, 1-9 | 4.6 | 53 |
| 188 | Increased biliary excretion of thyroxine by microsomal enzyme inducers. *Toxicology and Applied Pharmacology*, **2001**, 176, 187-94 | 4.6 | 45 |
| 187 | Strain differences in the toxicity of cadmium to trigeminal ganglia in mice. *Toxicology and Applied Pharmacology*, **2001**, 177, 200-7 | 4.6 | 12 |
| 186 | Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. *Molecular Pharmacology*, **2001**, 60, 302-9 | 4.3 | 204 |
| 185 | Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. *Toxicologic Pathology*, **2001**, 29, 34-40 | 2.1 | 83 |
| 184 | Cloning, expression, and ontogeny of mouse organic anion-transporting polypeptide-5, a kidney-specific organic anion transporter. *Biochemical and Biophysical Research Communications*, **2001**, 280, 92-8 | 3.4 | 33 |
| 183 | Genomic organization and tissue-specific expression of splice variants of mouse organic anion transporting polypeptide 2. *Biochemical and Biophysical Research Communications*, **2001**, 281, 431-9 | 3.4 | 14 |
| 182 | Use of genetically altered animal models in understanding the role of metallothionein in cadmium toxicity. *Pure and Applied Chemistry*, **2000**, 72, 1023-1026 | 2.1 | 3 |
| 181 | Effects of molybdate and pentachlorophenol on the sulfation of acetaminophen. *Toxicology*, **2000**, 146, 23-35 | 4.4 | 7 |
| 180 | Chronic combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice. *Toxicology*, **2000**, 147, 157-66 | 4.4 | 81 |
| 179 | Effects of microsomal enzyme inducers on outer-ring deiodinase activity toward thyroid hormones in various rat tissues. *Toxicology and Applied Pharmacology*, **2000**, 163, 240-8 | 4.6 | 57 |
| 178 | Cadmium decreases gap junctional intercellular communication in mouse liver. *Toxicological Sciences*, **2000**, 57, 156-66 | 4.4 | 50 |
| 177 | Full-length cDNA cloning and genomic organization of the mouse liver-specific organic anion transporter-1 (lst-1). *Biochemical and Biophysical Research Communications*, **2000**, 272, 563-70 | 3.4 | 39 |
| 176 | Cloning of the full-length coding sequence of rat liver-specific organic anion transporter-1 (rlst-1) and a splice variant and partial characterization of the rat lst-1 gene. *Biochemical and Biophysical Research Communications*, **2000**, 274, 79-86 | 3.4 | 36 |
| 175 | Metallothionein-null mice are highly susceptible to the hematotoxic and immunotoxic effects of chronic CdCl2 exposure. *Toxicology and Applied Pharmacology*, **1999**, 159, 98-108 | 4.6 | 68 |
| 174 | Effects of microsomal enzyme inducers on thyroid-follicular cell proliferation, hyperplasia, and hypertrophy. *Toxicology and Applied Pharmacology*, **1999**, 160, 163-70 | 4.6 | 92 |
| 173 | Metallothionein-I and -II knock-out mice are not more sensitive than control mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. *Neuroscience Letters*, **1999**, 273, 113-6 | 3.3 | 7 |
| 172 | Metallothionein-I transgenic mice are not protected from gamma-radiation. *Toxicology Letters*, **1999**, 104, 183-7 | 4.4 | 14 |

| | | | |
|---|---|---|---|
| 171 | Effects of molybdate and pentachlorophenol on the sulfation of alpha-naphthol. *Toxicology Letters*, **1999**, 106, 1-8 | 4.4 | 8 |
| 170 | The UDP-glucuronyltransferase inducers, phenobarbital and pregnenolone-16alpha-carbonitrile, enhance thyroid-follicular cell apoptosis: association with TGF-beta1 expression. *Toxicology Letters*, **1999**, 106, 143-50 | 4.4 | 9 |
| 169 | Metallothionein: an intracellular protein to protect against cadmium toxicity. *Annual Review of Pharmacology and Toxicology*, **1999**, 39, 267-94 | 17.9 | 895 |
| 168 | Metallothionein-I/II knockout mice are sensitive to acetaminophen-induced hepatotoxicity **1999**, 547-552 | | 2 |
| 167 | Metallothionein-null mice are susceptible to chronic CdCl2-induced nephropathy: Cd-induced renal injury is not necessarily mediated by CdMT **1999**, 453-457 | | |
| 166 | Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. *Toxicology and Applied Pharmacology*, **1998**, 149, 24-31 | 4.6 | 97 |
| 165 | Cadmium-induced apoptosis in mouse liver. *Toxicology and Applied Pharmacology*, **1998**, 149, 203-9 | 4.6 | 222 |
| 164 | Effects of molybdate and pentachlorophenol on the sulfation of dehydroepiandrosterone. *Toxicology and Applied Pharmacology*, **1998**, 151, 105-9 | 4.6 | 3 |
| 163 | Acute CdMT injection is not a good model to study chronic Cd nephropathy: comparison of chronic CdCl2 and CdMT exposure with acute CdMT injection in rats. *Toxicology and Applied Pharmacology*, **1998**, 153, 48-58 | 4.6 | 67 |
| 162 | Regulation of sulfotransferase mRNA expression in male and female rats of various ages. *Chemico-Biological Interactions*, **1998**, 109, 299-313 | 5 | 65 |
| 161 | Susceptibility of MT-Null Mice to Chronic CdCl2-Induced Nephrotoxicity Indicates That Renal Injury Is Not Mediated by the CdMT Complex. *Toxicological Sciences*, **1998**, 46, 197-203 | 4.4 | 86 |
| 160 | Metallothionein transgenic and knock-out mouse models in the study of cadmium toxicity. *Journal of Toxicological Sciences*, **1998**, 23 Suppl 2, 97-102 | 1.9 | 83 |
| 159 | Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. *Drug Metabolism Reviews*, **1997**, 29, 79-102 | 7 | 117 |
| 158 | Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation. *FASEB Journal*, **1997**, 11, 404-18 | 0.9 | 269 |
| 157 | Metallothioneins in brain--the role in physiology and pathology. *Toxicology and Applied Pharmacology*, **1997**, 142, 229-42 | 4.6 | 164 |
| 156 | Cadmium accumulation and metallothionein expression in brain of mice at different stages of development. *Toxicology Letters*, **1996**, 84, 127-33 | 4.4 | 48 |
| 155 | Hepatocytes from metallothionein-I and II knock-out mice are sensitive to cadmium- and tert-butylhydroperoxide-induced cytotoxicity. *Toxicology Letters*, **1996**, 87, 139-45 | 4.4 | 52 |
| 154 | Induction of metallothionein mRNA and proteinin primary murine neuron cultures. *Toxicology and Applied Pharmacology*, **1996**, 141, 1-7 | 4.6 | 61 |

| | | | |
|---|---|---|---|
| 153 | Induction of metallothionein mRNA and protein in murine astrocyte cultures. *Toxicology and Applied Pharmacology*, **1996**, 136, 94-100 | 4.6 | 85 |
| 152 | Metallothionein-I and -II knock-out mice are sensitive to cadmium-induced liver mRNA expression of c-jun and p53. *Toxicology and Applied Pharmacology*, **1996**, 136, 229-35 | 4.6 | 73 |
| 151 | Distribution and retention of cadmium in metallothionein I and II null mice. *Toxicology and Applied Pharmacology*, **1996**, 136, 260-8 | 4.6 | 52 |
| 150 | Molybdate impairs glycosaminoglycan sulfation in rat cartilage. *Toxicology and Applied Pharmacology*, **1996**, 136, 354-60 | 4.6 | 5 |
| 149 | Metallothionein-I-transgenic mice are not protected from acute cadmium-metallothionein-induced nephrotoxicity. *Toxicology and Applied Pharmacology*, **1996**, 137, 307-15 | 4.6 | 21 |
| 148 | Different mechanism of saturation of acetaminophen sulfate conjugation in mice and rats. *Toxicology and Applied Pharmacology*, **1996**, 139, 128-34 | 4.6 | 35 |
| 147 | Absorption and Distribution of Cadmium in Metallothionein-I Transgenic Mice. *Toxicological Sciences*, **1996**, 29, 294-300 | 4.4 | 1 |
| 146 | Chemical modulation of metallothionein I and III mRNA in mouse brain. *Neurochemistry International*, **1995**, 27, 43-58 | 4.4 | 73 |
| 145 | Protection by Zinc-Metallothionein (ZnMT) against Cadmium-Metallothionein-Induced Nephrotoxicity. *Toxicological Sciences*, **1995**, 26, 99-106 | 4.4 | |
| 144 | Hepatotoxicity of Metals **1995**, 339-361 | | 1 |
| 143 | Environmental Epidemiology for Chemists. *Advances in Chemistry Series*, **1994**, 39-51 | | |
| 142 | Zinc-Induced Arsenite Tolerance in Mice. *Toxicological Sciences*, **1994**, 23, 32-37 | 4.4 | 3 |
| 141 | Nutritionally and chemically induced impairment of sulfate activation and sulfation of xenobiotics in vivo. *Chemico-Biological Interactions*, **1994**, 92, 169-77 | 5 | 4 |
| 140 | The effect of Chinese hepatoprotective medicines on experimental liver injury in mice. *Journal of Ethnopharmacology*, **1994**, 42, 183-91 | 5 | 96 |
| 139 | The effects of 10 triterpenoid compounds on experimental liver injury in mice. *Fundamental and Applied Toxicology*, **1994**, 22, 34-40 | | 83 |
| 138 | Zinc-induced arsenite tolerance in mice. *Fundamental and Applied Toxicology*, **1994**, 23, 32-7 | | 54 |
| 137 | Species variation in hepatic metallothionein. *Toxicology Letters*, **1994**, 74, 23-33 | 4.4 | 35 |
| 136 | Induction of metallothionein by superantigenic bacterial exotoxin: probable involvement of the immune system. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1994**, 1225, 171-9 | 6.9 | 4 |

| | | | |
|---|---|---|---|
| 135 | In Vitro and In Vivo Studies on the Degradation of Metallothionein. *Environmental Health Perspectives*, **1994**, 102, 141 | 8.4 | 7 |
| 134 | In Vivo Microdialysis Sampling of Phenol and Phenyl Glucuronide in the Blood of Unanesthetized Rainbow Trout: Implications for Toxicokinetic Studies. *Toxicological Sciences*, **1993**, 20, 190-198 | 4.4 | |
| 133 | Induction of Metallothionein by Arsenicals in Mice. *Toxicological Sciences*, **1993**, 20, 184-189 | 4.4 | 3 |
| 132 | Reduction of Thyroid Hormone Levels by Glucuronosyltransferase Inducers. *Drug Metabolism and Pharmacokinetics*, **1993**, 8, 621-621 | | |
| 131 | Protective effects of zinc on cultured rat primary hepatocytes to metals with low affinity for metallothionein. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1992**, 35, 51-62 | 3.2 | 16 |
| 130 | Bromobenzene-glutathione excretion into bile reflects toxic activation of bromobenzene in rats. *Toxicology Letters*, **1992**, 60, 227-36 | 4.4 | 14 |
| 129 | UDP-glucuronosyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. *Toxicology and Applied Pharmacology*, **1992**, 113, 36-42 | 4.6 | 152 |
| 128 | Effect of lipoic acid on biliary excretion of glutathione and metals. *Toxicology and Applied Pharmacology*, **1992**, 114, 88-96 | 4.6 | 50 |
| 127 | In vitro degradation of apo-, zinc-, and cadmium-metallothionein by cathepsins B, C, and D. *Toxicology and Applied Pharmacology*, **1992**, 116, 117-24 | 4.6 | 27 |
| 126 | Induction of hepatic metallothionein by paraquat. *Toxicology and Applied Pharmacology*, **1992**, 117, 233-41 | 4.6 | 48 |
| 125 | Accumulation and degradation of the protein moiety of cadmium-metallothionein (CdMT) in the mouse kidney. *Toxicology and Applied Pharmacology*, **1992**, 117, 242-8 | 4.6 | 50 |
| 124 | Degradation and metal composition of hepatic isometallothioneins in rats. *Toxicology and Applied Pharmacology*, **1992**, 112, 24-31 | 4.6 | 21 |
| 123 | Effects of microsomal enzyme inducers upon UDP-glucuronic acid concentration and UDP-glucuronosyltransferase activity in the rat intestine and liver. *Toxicology and Applied Pharmacology*, **1992**, 115, 253-60 | 4.6 | 29 |
| 122 | Rat liver microsomal UDP-glucuronosyltransferase activity toward thyroxine: characterization, induction, and form specificity. *Toxicology and Applied Pharmacology*, **1992**, 115, 261-7 | 4.6 | 54 |
| 121 | Role of hepatic lysosomes in the degradation of metallothionein. *Toxicology and Applied Pharmacology*, **1992**, 115, 64-71 | 4.6 | 19 |
| 120 | Separation and quantification of isometallothioneins by high-performance liquid chromatography-atomic absorption spectrometry. *Methods in Enzymology*, **1991**, 205, 190-8 | 1.7 | 10 |
| 119 | Induction of metallothionein in primary rat hepatocyte cultures. *Methods in Enzymology*, **1991**, 205, 567-74 | 1.7 | 12 |
| 118 | Protective effect of pregnenolone-16 alpha-carbonitrile on acetaminophen-induced hepatotoxicity in hamsters. *Toxicology and Applied Pharmacology*, **1991**, 109, 305-13 | 4.6 | 31 |

| | | | |
|---|---|---|---|
| 117 | Hepatic isometallothioneins in mice: induction in adults and postnatal ontogeny. *Toxicology and Applied Pharmacology*, **1990**, 104, 267-75 | 4.6 | 19 |
| 116 | Ethanol decreases cadmium hepatotoxicity in rats: possible role of hepatic metallothionein induction. *Toxicology and Applied Pharmacology*, **1990**, 106, 448-55 | 4.6 | 18 |
| 115 | Induction of Metallothionein. *Journal of the American College of Toxicology*, **1989**, 8, 1315-1321 | | 30 |
| 114 | Dosage-dependent absorption of cadmium in the rat intestine measured in situ. *Toxicology and Applied Pharmacology*, **1989**, 100, 41-50 | 4.6 | 38 |
| 113 | Regulation of the isoforms of metallothionein. *Biological Trace Element Research*, **1989**, 21, 119-29 | 4.5 | 26 |
| 112 | Biliary Excretion of Thiols and Their Role in Elimination of Methylmercury. *Proceedings in Life Sciences*, **1989**, 141-153 | | |
| 111 | Effect of butylated hydroxyanisole on hepatic glucuronidation and biliary excretion of drugs in mice. *Journal of Pharmacy and Pharmacology*, **1988**, 40, 237-42 | 4.8 | 2 |
| 110 | Species variations in biliary excretion of glutathione-related thiols and methylmercury. *Toxicology and Applied Pharmacology*, **1988**, 93, 351-9 | 4.6 | 29 |
| 109 | Mechanisms of regulation of rat hepatic metallothionein-I and metallothionein-II levels following administration of zinc. *Toxicology and Applied Pharmacology*, **1988**, 92, 1-9 | 4.6 | 32 |
| 108 | Ontogeny and induction of hepatic isometallothioneins in immature rats. *Toxicology and Applied Pharmacology*, **1988**, 92, 10-7 | 4.6 | 25 |
| 107 | Kidney synthesizes less metallothionein than liver in response to cadmium chloride and cadmium-metallothionein. *Toxicology and Applied Pharmacology*, **1988**, 92, 95-102 | 4.6 | 54 |
| 106 | Effect of glutathione depletion on sulfate activation and sulfate ester formation in rats. *Biochemical Pharmacology*, **1988**, 37, 4307-12 | 6 | 23 |
| 105 | Nephrotoxicity of Intravenously Injected Cadmium-Metallothionein: Critical Concentration and Tolerance. *Toxicological Sciences*, **1988**, 10, 98-108 | 4.4 | |
| 104 | Biliary excretion. *Journal of Clinical Pharmacology*, **1987**, 27, 537-41 | 2.9 | 12 |
| 103 | Induction of metallothionein in rat primary hepatocyte cultures: evidence for direct and indirect induction. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1987**, 22, 163-74 | 3.2 | 43 |
| 102 | Studies on the pregnenolone-16 alpha-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase. *Biochemical Pharmacology*, **1987**, 36, 3859-66 | 6 | 67 |
| 101 | Induction of metallothionein by steroids in rat primary hepatocyte cultures. *Toxicology and Applied Pharmacology*, **1987**, 87, 381-8 | 4.6 | 35 |
| 100 | Induction of hepatic metallothionein following administration of urethane. *Toxicology and Applied Pharmacology*, **1987**, 87, 457-63 | 4.6 | 14 |

| | | | |
|---|---|---|---|
| 99 | Utilization of methionine as a sulfhydryl source for metallothionein synthesis in rat primary hepatocyte cultures. *Toxicology and Applied Pharmacology*, **1987**, 87, 276-83 | 4.6 | 23 |
| 98 | Metals, Hepatocytes, and Toxicology **1987**, 159-187 | | 4 |
| 97 | Cadmium uptake by rat red blood cells. *Toxicology*, **1986**, 42, 111-9 | 4.4 | 31 |
| 96 | High-performance liquid chromatographic analysis of glutathione and its thiol and disulfide degradation products. *Biomedical Applications*, **1986**, 381, 259-70 | | 59 |
| 95 | Dosage-dependent disposition of cadmium administered orally to rats. *Toxicology and Applied Pharmacology*, **1986**, 84, 159-67 | 4.6 | 77 |
| 94 | Separation and quantitation of metallothioneins by high-performance liquid chromatography coupled with atomic absorption spectrophotometry. *Analytical Biochemistry*, **1986**, 153, 305-14 | 3.1 | 56 |
| 93 | Comparison of methods of metallothionein quantification: cadmium radioassay, mercury radioassay, and radioimmunoassay. *Toxicology and Applied Pharmacology*, **1985**, 79, 524-7 | 4.6 | 31 |
| 92 | Cadmium-induced hepatic and renal injury in chronically exposed rats: likely role of hepatic cadmium-metallothionein in nephrotoxicity. *Toxicology and Applied Pharmacology*, **1985**, 77, 414-26 | 4.6 | 225 |
| 91 | Induction of hepatic metallothionein in mouse liver following administration of chelating agents. *Toxicology and Applied Pharmacology*, **1985**, 80, 467-72 | 4.6 | 34 |
| 90 | Effect of cobalt on biliary excretion of bilirubin and glutathione. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1985**, 15, 813-22 | 3.2 | 3 |
| 89 | Age- and sex-dependent induction of liver microsomal benzo[a]pyrene hydroxylase activity in rats treated with pregnenolone-16 alpha-carbonitrile (PCN). *Carcinogenesis*, **1985**, 6, 617-24 | 4.6 | 24 |
| 88 | Hepatic presystemic elimination of diethylstilbestrol by rats and effect of pretreatment with inducers of UDP-glucuronosyltransferase. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1985**, 16, 615-29 | 3.2 | 2 |
| 87 | Concentration of Metallothionein in Major Organs of Rats after Administration of Various Metals. *Toxicological Sciences*, **1985**, 5, 473-477 | 4.4 | 6 |
| 86 | Role of Sulfhydryls in the Hepatotoxicity of Organic and Metallic Compounds. *Toxicological Sciences* , **1985**, 5, 806-815 | 4.4 | 4 |
| 85 | An isocratic reverse-phase high-performance liquid chromatographic assay for adenine nucleotides in rat liver. *Journal of Pharmacological Methods*, **1985**, 14, 189-97 | | 10 |
| 84 | Mechanism of manganese-induced tolerance to cadmium lethality and hepatotoxicity. *Biochemical Pharmacology*, **1985**, 34, 1371-9 | 6 | 26 |
| 83 | Tolerance to cadmium-induced toxicity depends on presynthesized metallothionein in liver. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1984**, 14, 803-12 | 3.2 | 75 |
| 82 | Time course of cadmium-induced ultrastructural changes in rat liver. *Toxicology and Applied Pharmacology*, **1984**, 76, 150-60 | 4.6 | 94 |

| | | | |
|---|---|---|---|
| 81 | Changes in hepatic glutathione concentration modify cadmium-induced hepatotoxicity. *Toxicology and Applied Pharmacology*, **1984**, 72, 530-8 | 4.6 | 82 |
| 80 | Metallothionein-like proteins in human placenta and fetal membranes. *Toxicology and Applied Pharmacology*, **1984**, 74, 179-84 | 4.6 | 44 |
| 79 | Transient induction of hepatic metallothionein following oral ethanol administration. *Toxicology and Applied Pharmacology*, **1984**, 74, 230-6 | 4.6 | 52 |
| 78 | Distribution of cadmium after oral administration of cadmium-thionein to mice. *Toxicology and Applied Pharmacology*, **1984**, 74, 237-43 | 4.6 | 29 |
| 77 | Zinc-induced tolerance to cadmium hepatotoxicity. *Toxicology and Applied Pharmacology*, **1984**, 74, 299-307 | 4.6 | 135 |
| 76 | Tolerance to cadmium-induced hepatotoxicity following cadmium pretreatment. *Toxicology and Applied Pharmacology*, **1984**, 74, 308-13 | 4.6 | 91 |
| 75 | Postnatal ontogeny of metallothionein in various organs of the rat. *Toxicology and Applied Pharmacology*, **1984**, 74, 314-20 | 4.6 | 53 |
| 74 | Resistance to cadmium-induced hepatotoxicity in immature rats. *Toxicology and Applied Pharmacology*, **1984**, 74, 321-9 | 4.6 | 59 |
| 73 | Relative in vitro affinity of hepatic metallothionein for metals. *Toxicology Letters*, **1984**, 20, 33-9 | 4.4 | 135 |
| 72 | Decreased glucuronidation of bilirubin by diethyl ether anesthesia. *Biochemical Pharmacology*, **1984**, 33, 2813-4 | 6 | 15 |
| 71 | Interaction of metals and carbon tetrachloride on lipid peroxidation and hepatotoxicity. *Toxicology and Applied Pharmacology*, **1983**, 71, 316-22 | 4.6 | 39 |
| 70 | Altered subcellular distribution of cadmium following cadmium pretreatment: possible mechanism of tolerance to cadmium-induced lethality. *Toxicology and Applied Pharmacology*, **1983**, 70, 195-203 | 4.6 | 130 |
| 69 | Isolated rat hepatocytes as a model system for screening chelators for use in cadmium intoxication. *Toxicology and Applied Pharmacology*, **1983**, 67, 257-63 | 4.6 | 16 |
| 68 | Minimal role of metallothionein in decreased chelator efficacy for cadmium. *Toxicology and Applied Pharmacology*, **1983**, 68, 392-8 | 4.6 | 41 |
| 67 | Disposition of metals after portal and systemic administration to rats. *Toxicology and Applied Pharmacology*, **1983**, 68, 442-50 | 4.6 | 3 |
| 66 | Hepatic phase I and phase II biotransformations in quail and trout: comparison to other species commonly used in toxicity testing. *Toxicology and Applied Pharmacology*, **1983**, 67, 430-41 | 4.6 | 103 |
| 65 | Protective effects of chromium on the toxicity of cadmium in vivo. *Toxicology*, **1983**, 28, 147-53 | 4.4 | 6 |
| 64 | Effects of phospholipase A2 inhibitors on diethyl maleate-induced lipid peroxidation and cellular injury in isolated rat hepatocytes. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1982**, 9, 439-50 | 3.2 | 17 |

| | | | |
|---|---|---|---|
| 63 | Lack of protection against chemically induced injury to isolated hepatocytes by omission of calcium from the incubation medium. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1982**, 9, 267-76 | 3.2 | 39 |
| 62 | On the disulfiram-like activity of moxalactam. *Clinical Pharmacology and Therapeutics*, **1982**, 32, 347-55 | 6.1 | 24 |
| 61 | Uptake of bile acids by isolated rat hepatocytes. *Biochemical Pharmacology*, **1982**, 31, 211-6 | 6 | 75 |
| 60 | Acute exposure to cadmium causes severe liver injury in rats. *Toxicology and Applied Pharmacology*, **1982**, 65, 302-13 | 4.6 | 217 |
| 59 | Comparison of Biliary excretion of organic anions in mice and rats. *Toxicology and Applied Pharmacology*, **1982**, 63, 13-20 | 4.6 | 14 |
| 58 | Decreased effectiveness of chelation therapy with time after acute cadmium poisoning. *Toxicology and Applied Pharmacology*, **1982**, 63, 173-80 | 4.6 | 69 |
| 57 | Induction studies on the functional heterogeneity of rat liver UDP-glucuronosyltransferases. *Toxicology and Applied Pharmacology*, **1982**, 64, 439-46 | 4.6 | 96 |
| 56 | The effect of repeated administration of several chelators on the distribution and excretion of cadmium. *Toxicology and Applied Pharmacology*, **1982**, 66, 361-7 | 4.6 | 33 |
| 55 | Evaluation of hepatic storage of sulfobromophthalein in rats and dogs. *Toxicology*, **1982**, 25, 261-70 | 4.4 | 3 |
| 54 | Zinc uptake by isolated rat hepatocytes. *Biochimica Et Biophysica Acta - Biomembranes*, **1981**, 640, 693-7 | 3.8 | 34 |
| 53 | Interaction of metal ions with cadmium-induced cellular toxicity. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1981**, 7, 149-58 | 3.2 | 53 |
| 52 | Choleretic effect of valproic acid in the rat. *Hepatology*, **1981**, 1, 341-7 | 11.2 | 26 |
| 51 | Induction of metallothionein by adrenocortical steroids. *Toxicology*, **1981**, 20, 275-9 | 4.4 | 55 |
| 50 | Relationship between liver and kidney levels of glutathione and metallothionein in rats. *Toxicology*, **1981**, 19, 39-47 | 4.4 | 73 |
| 49 | Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion, and distribution of cadmium. *Toxicology and Applied Pharmacology*, **1981**, 58, 452-60 | 4.6 | 110 |
| 48 | Inhibition of lipid peroxidation without prevention of cellular injury in isolated rat hepatocytes. *Toxicology and Applied Pharmacology*, **1981**, 58, 8-18 | 4.6 | 100 |
| 47 | Copper toxicity in isolated rat hepatocytes. *Toxicology and Applied Pharmacology*, **1981**, 58, 211-20 | 4.6 | 45 |
| 46 | Comparison of the effects of metals on cellular injury and lipid peroxidation in isolated rat hepatocytes. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1981**, 7, 139-47 | 3.2 | 96 |

| | | | |
|---|---|---|---|
| 45 | Metallothionein as a trap for reactive organic intermediates. *Advances in Experimental Medicine and Biology*, **1981**, 136 Pt A, 633-46 | 3.6 | 10 |
| 44 | Comparison of the toxicity and tissue distribution of cadmium in newborn and adult rats after repeated administration. *Toxicology and Applied Pharmacology*, **1980**, 56, 317-25 | 4.6 | 46 |
| 43 | Dose-response effects of various metal ions on rat liver metallothionein, glutathione, heme oxygenase, and cytochrome P-450. *Toxicology and Applied Pharmacology*, **1980**, 55, 393-402 | 4.6 | 213 |
| 42 | Binding of glutathione-depleting agents to metallothionein. *Toxicology and Applied Pharmacology*, **1980**, 54, 229-37 | 4.6 | 24 |
| 41 | Cadmium toxicity and lipid peroxidation in isolated rat hepatocytes. *Toxicology and Applied Pharmacology*, **1980**, 53, 470-80 | 4.6 | 211 |
| 40 | The effect of ethylenediaminetetraacetic acid (EDTA) and EDTA plus salicylate on acute cadmium toxicity and distribution. *Toxicology and Applied Pharmacology*, **1980**, 53, 510-4 | 4.6 | 11 |
| 39 | Tissue distribution and retention of cadmium in rats during postnatal development: minimal role of hepatic metallothionein. *Toxicology and Applied Pharmacology*, **1980**, 53, 343-53 | 4.6 | 42 |
| 38 | Increase in hepatic metallothionein in rats treated with alkylating agents. *Toxicology and Applied Pharmacology*, **1979**, 51, 19-27 | 4.6 | 90 |
| 37 | Protection of carbon tetrachloride-induced hepatotoxicity by zinc: role of metallothionein. *Toxicology and Applied Pharmacology*, **1979**, 51, 107-16 | 4.6 | 118 |
| 36 | Hepatotoxicity of carbon tetrachloride in developing rats. *Toxicology and Applied Pharmacology*, **1979**, 50, 347-54 | 4.6 | 21 |
| 35 | Importance of hepatic function on the plasma disappearance and biliary excretion of hexachlorophene. *Toxicology and Applied Pharmacology*, **1979**, 49, 113-7 | 4.6 | 5 |
| 34 | Effect of spironolactone on the bilitary excretion and distribution of metals. *Toxicology and Applied Pharmacology*, **1979**, 50, 41-8 | 4.6 | 4 |
| 33 | Biliary excretion of silver in the rat, rabbit, and dog. *Toxicology and Applied Pharmacology*, **1979**, 50, 49-55 | 4.6 | 25 |
| 32 | Biliary excretion of drugs in man. *Clinical Pharmacokinetics*, **1979**, 4, 368-79 | 6.2 | 101 |
| 31 | The relationship of metallothionein to the toxicity of cadmium after prolonged oral administration to rats. *Toxicology and Applied Pharmacology*, **1978**, 46, 39-54 | 4.6 | 106 |
| 30 | Biliary Excretion **1977**, 537-553 | | 1 |
| 29 | Comparison of methods for estimating hepatic metallothionein in rats. *Toxicology and Applied Pharmacology*, **1977**, 42, 583-8 | 4.6 | 84 |
| 28 | Toxicity and distribution of cadmium administered to rats at sublethal doses. *Toxicology and Applied Pharmacology*, **1977**, 41, 667-80 | 4.6 | 139 |

| | | | |
|---|---|---|---|
| 27 | Biliary excretion of cadmium in the rat, rabbit, and dog. *Toxicology and Applied Pharmacology*, **1977**, 41, 101-12 | 4.6 | 41 |
| 26 | Studies on the mechanism of spironolactone protection against indomethacin toxicity. *Toxicology and Applied Pharmacology*, **1976**, 38, 127-35 | 4.6 | 15 |
| 25 | Effect of microsomal enzyme inducers on the biliary excretion of an exogenous load of bilirubin in newborn rats. *Experimental Biology and Medicine*, **1976**, 153, 370-3 | 3.7 | 5 |
| 24 | Biliary excretion of metals. *Drug Metabolism Reviews*, **1976**, 5, 165-96 | 7 | 62 |
| 23 | Effects of acute administration of taurocholic and taurochenodeoxycholic acid on biliary lipid excretion in the rat. *Experimental Biology and Medicine*, **1976**, 151, 198-202 | 3.7 | 25 |
| 22 | Biliary excretion of xenobiotics. *CRC Critical Reviews in Toxicology*, **1975**, 4, 1-30 | | 23 |
| 21 | Extrahpetic distribution of sulfobromophthalein. *Canadian Journal of Physiology and Pharmacology*, **1975**, 53, 120-3 | 2.4 | 16 |
| 20 | Biliary excretion of mercury compounds. *Toxicology and Applied Pharmacology*, **1975**, 33, 356-65 | 4.6 | 34 |
| 19 | Effect of spironolactone on the distribution of mercury. *Toxicology and Applied Pharmacology*, **1975** , 33, 366-75 | 4.6 | 13 |
| 18 | Hepatic uptake of cardiac glycosides in newborn rats, rabbits and dogs. *Biochemical Pharmacology*, **1975**, 24, 923-5 | 6 | 8 |
| 17 | Bile flow and composition during bile acid depletion and administration. *Canadian Journal of Physiology and Pharmacology*, **1974**, 52, 334-48 | 2.4 | 34 |
| 16 | Comparison of the toxicity of chemicals in newborn rats to bile duct-ligated and sham-operated rats and mice. *Toxicology and Applied Pharmacology*, **1973**, 24, 37-44 | 4.6 | 32 |
| 15 | The effect of altered hepatic function on the toxicity, plasma disappearance and biliary excretion of diethylstilbestrol. *Toxicology and Applied Pharmacology*, **1973**, 24, 142-9 | 4.6 | 17 |
| 14 | Comparison of the choleretic properties of bile acids. *European Journal of Pharmacology*, **1973**, 23, 270-5 | 5.3 | 17 |
| 13 | Effect of alteration in body temperature on the biliary excretion of copper. *Experimental Biology and Medicine*, **1973**, 144, 8-12 | 3.7 | 11 |
| 12 | Species difference in the plasma disappearance and biliary excretion of procaine amide ethobromide. *Experimental Biology and Medicine*, **1972**, 139, 1445-50 | 3.7 | 3 |
| 11 | Species differences in the choleretic response to bile salts. *Journal of Physiology*, **1972**, 224, 259-69 | 3.9 | 15 |
| 10 | Gas-liquid-chromatographic determination of bile acids in bile. *Clinica Chimica Acta*, **1971**, 35, 225-9 | 6.2 | 42 |

| | | | |
|---|---|---|---|
| 9 | Plasma disappearance and biliary excretion of sulfobromophthalein and phenol-3,6-dibromphthalein disulfonate after microsomal enzyme induction. *Biochemical Pharmacology*, **1970**, 19, 1241-9 | 6 | 48 |
| 8 | Plasma disappearance and biliary excretion of indocyanine green in rats, rabbits, and dogs. *Toxicology and Applied Pharmacology*, **1969**, 15, 374-84 | 4.6 | 57 |
| 7 | Maximal biliary excretion of bilirubin and sulfobromophthalein during various rates of infusion in rats of different weights and strains. *Toxicology and Applied Pharmacology*, **1969**, 15, 143-51 | 4.6 | 19 |
| 6 | Comparison of the biochemical alterations elicited in livers from rats treated with carbon tetrachloride, chloroform, 1,1,2-trichloroethane and 1,1,1-trichloroethane. *Biochemical Pharmacology*, **1969**, 18, 2019-27 | 6 | 178 |
| 5 | Effect of carbon tetrachloride on the metabolism, storage, and excretion of sulfobromophthalein. *Toxicology and Applied Pharmacology*, **1968**, 12, 132-9 | 4.6 | 40 |
| 4 | Maximum biliary excretion of bilirubin and sulfobromophthalein during anesthesia-induced alteration of rectal temperature. *Experimental Biology and Medicine*, **1967**, 125, 313-6 | 3.7 | 53 |
| 3 | Relative effects of various chlorinated hydrocarbons on liver and kidney function in dogs. *Toxicology and Applied Pharmacology*, **1967**, 10, 119-31 | 4.6 | 91 |
| 2 | Relative effects of various chlorinated hydrocarbons on liver and kidney function in mice. *Toxicology and Applied Pharmacology*, **1966**, 9, 139-51 | 4.6 | 155 |
| 1 | Age- and Gender-Related Differences in Xenobiotic Transporter Expression589-617 | | |